To evaluate the relationships between bone mineral metabolism markers (osteoprotegerin, fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a 7 year follow-up.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
250
dosage of plasma osteoprotegerin
dosage of plasma fibroblast growth factor 23
measurement of vascular calcification score by multidetection computerized tomography
AIDER
Montpellier, France
RECRUITINGCHU Montpellier, Cardiology department
Montpellier, France
ACTIVE_NOT_RECRUITINGCHU Montpellier, Endocrinology department
Montpellier, France
Occurence of at least one cardiovascular event during the 7 year follow-up according to osteoprotegerin level at inclusion
osteoprotegerin will be measured in picomol/L
Time frame: 7 years after inclusion
Occurence of at least one cardiovascular event during the 7 year follow-up according to fibroblast growth factor 23 level at inclusion
fibroblast growth factor 23 will be measured in RU/milliliter
Time frame: 7 years after inclusion
Occurence of at least one cardiovascular event during the 7 year follow-up according to vascular calcification score at inclusion
Time frame: 7 years after inclusion
Mortality
Time frame: 7 years after inclusion
Kidney functions
values of creatinine
Time frame: during the 7 year follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CHU Montpellier, Intensive care unit
Montpellier, France
ACTIVE_NOT_RECRUITINGCHU Montpellier, Internal medicine department
Montpellier, France
ACTIVE_NOT_RECRUITINGCHU Montpellier, Nephrology department
Montpellier, France
RECRUITINGAIDER
Saint-Jean-de-Védas, France
NOT_YET_RECRUITING